AUTHOR=Zhang Lu-yang , Guo Qing , Guan Ge-fei , Cheng Wen , Cheng Peng , Wu An-hua 

TITLE=Integrin Beta 5 Is a Prognostic Biomarker and Potential Therapeutic Target in Glioblastoma

JOURNAL=Frontiers in Oncology

VOLUME=9

YEAR=2019

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.00904

DOI=10.3389/fonc.2019.00904

ISSN=2234-943X

ABSTRACT=<p><bold>Background:</bold> Glioblastoma (GBM) is the most lethal cancer of the central nervous system. Integrin beta 5 (<italic>ITGB5</italic>) is thought to be involved in intercellular signal transduction and regulation of tumor initiation and progression. However, the function of <italic>ITGB5</italic> in GBM is not known.</p><p><bold>Methods:</bold> To address this question, we evaluated the expression level of <italic>ITGB5</italic> in clinical specimens by immunohistochemistry and western blotting, as well as the association between <italic>ITGB5</italic> expression and GBM patient survival using data from Chinese Glioma Genome Atlas and The Cancer Genome Atlas. The biological function of <italic>ITGB5</italic> in GBM was investigated by Gene Ontology, gene set enrichment, and <italic>in vitro</italic> loss-of-function experiments using glioma cells.</p><p><bold>Results:</bold> Among integrin family members, <italic>ITGB5</italic> showed the greatest difference in expression between low-grade glioma and GBM. Elevated ITGB5 expression was highly correlated with glioma progression and a mesenchymal subtype and poor survival in GBM patients. <italic>ITGB5</italic> was found to be associated with regulation of the immune response and angiogenesis in GBM, and was required for migration and invasion of glioma cells and tube formation by endothelial cells.</p><p><bold>Conclusions:</bold> These data indicate that ITGB5 can serve as a predictive biomarker for GBM patient survival and is a potential therapeutic target in GBM treatment.</p>